高级搜索
朱晓霞, 贾瑜琦, 刘畅, 弓韬, 李高鹏, 张宏伟, 于保锋. 靶向药物联合应用对肝癌细胞SK-Hep-1增殖的影响及其机制[J]. 肿瘤防治研究, 2022, 49(11): 1126-1133. DOI: 10.3971/j.issn.1000-8578.2022.22.0157
引用本文: 朱晓霞, 贾瑜琦, 刘畅, 弓韬, 李高鹏, 张宏伟, 于保锋. 靶向药物联合应用对肝癌细胞SK-Hep-1增殖的影响及其机制[J]. 肿瘤防治研究, 2022, 49(11): 1126-1133. DOI: 10.3971/j.issn.1000-8578.2022.22.0157
ZHU Xiaoxia, JIA Yuqi, LIU Chang, GONG Tao, LI Gaopeng, ZHANG Hongwei, YU Baofeng. Effects and Mechanisms of Combined Application of Molecular Targeted Drugs on Proliferation of Hepatocellular Carcinoma SK-Hep-1 Cells[J]. Cancer Research on Prevention and Treatment, 2022, 49(11): 1126-1133. DOI: 10.3971/j.issn.1000-8578.2022.22.0157
Citation: ZHU Xiaoxia, JIA Yuqi, LIU Chang, GONG Tao, LI Gaopeng, ZHANG Hongwei, YU Baofeng. Effects and Mechanisms of Combined Application of Molecular Targeted Drugs on Proliferation of Hepatocellular Carcinoma SK-Hep-1 Cells[J]. Cancer Research on Prevention and Treatment, 2022, 49(11): 1126-1133. DOI: 10.3971/j.issn.1000-8578.2022.22.0157

靶向药物联合应用对肝癌细胞SK-Hep-1增殖的影响及其机制

Effects and Mechanisms of Combined Application of Molecular Targeted Drugs on Proliferation of Hepatocellular Carcinoma SK-Hep-1 Cells

  • 摘要:
    目的 探讨靶向药物联合应用对多驱动基因调控增殖的肝癌细胞SK-Hep-1的影响及作用机制。
    方法 利用对肝癌细胞SK-Hep-1敏感的靶向药物(HG6-64-1、dasatinib、crizotinib、sunitinib)绘制单靶点动力学分析曲线和双相分析曲线,对SK-Hep-1细胞进行动力学分析;Western blot法检测这些靶向药物对SK-Hep-1细胞关键信号通路的影响;MTT法检测这些药物单用和联合应用对SK-Hep-1细胞增殖的影响。
    结果 与单靶点动力学分析曲线比较,双相分析曲线可更好拟合靶向药物对肝癌细胞SK-Hep-1的影响,并且预测出HG6-64-1、dasatinib和MK-2206三药联合应用能有效抑制SK-Hep-1细胞增殖。
    结论 双相动力学分析可以更好地定量描述多驱动增殖的肝癌细胞SK-Hep-1对靶向治疗的反应,联合使用HG6-64-1、dasatinib和MK-2206是治疗肝癌潜在的药物组合。

     

    Abstract:
    Objective To study the effects and mechanisms of molecular targeted drug combination on multi-driven proliferation hepatocellular carcinoma SK-Hep-1 cells.
    Methods Four molecular targeted drugs (HG6-64-1, Dasatinib, Crizotinib, and Sunitinib) were used to treat SK-Hep-1 cells, and the monophasic kinetic analysis curve and two-phase analysis curve were drawn. Western blot analysis was used to detect the effects of the above drugs on key signaling pathways in SK-Hep-1 cells. MTT assay was used to detect the effects of the above drugs and their combination on the proliferation of SK-Hep-1 cells.
    Results Compared with the monophasic kinetic analysis curve, the biphase analysis curve could better fit the effects of molecular targeted drugs on SK-Hep-1 cells, which predicted that the combination of HG6-64-1, Dasatinib, and MK-2206 could effectively inhibit the proliferation of SK-Hep-1 cells.
    Conclusion Two-phase kinetic analysis can quantitatively describe the response of multi-driven proliferation hepatocellular carcinoma SK-Hep-1 cells to molecular targeted therapy. The combination of HG6-64-1, Dasatinib, and MK-2206 is a potential drug combination for the treatment of hepatocellular carcinoma.

     

/

返回文章
返回